Neurology pp 340-348 | Cite as

Parkinson’s Disease: Clinical Trials

  • J. K. Tsui
  • M. Schulzer
  • D. B. Calne
Conference paper

Abstract

Parkinson’s disease has been one of the most meticulously measured of all neurological disorders. Clinical trials have repeatedly played a crucial role in improving treatment, and because drugs are frequently employed as tools for the analysis of biological mechanisms, clinical trials have also made important contributions to an understanding of Parkinson’s disease. In this review of clinical trials in Parkinson’s disease, we shall discuss the following: diagnostic criteria, design of studies, methods of evaluation and analysis of results.

Keywords

Depression Torque Dopamine Covariance Titration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson S et al. (1980) Statistical methods for comparative studies; techniques for bias reduction. Wiley, New YorkCrossRefGoogle Scholar
  2. 2.
    Armitage P (1957) Restricted sequential procedures. Biometria 44: 9–26Google Scholar
  3. 3.
    Armitage P (1960) Sequential medical trials. Blackwell, OxfordGoogle Scholar
  4. 4.
    Canter GJ, deLaTorre R, Mier M (1961) A method for evaluating disability in patients with Parkinson’s disease. J Nerv Ment Dis 133: 143–147PubMedCrossRefGoogle Scholar
  5. 5.
    Chatfield C (1984) The analysis of time series: an introduction, 3rd edn. Chapman and Hall, LondonGoogle Scholar
  6. 6.
    Cochran WG (1983) Planning and analysis of observational studies. Wiley, New YorkCrossRefGoogle Scholar
  7. 7.
    Cox DR (1970) An analysis of binary data. Methuen, LondonGoogle Scholar
  8. 8.
    Duvoisin RC (1970) The evaluation of extra-pyramidal disease. In: de Ajuriagerra J (ed) Monoamines: noyaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 313–325Google Scholar
  9. 9.
    Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson’s disease. Neurology 31: 1356–1359PubMedGoogle Scholar
  10. 10.
    England AC, Schwab RS (1956) Post-operative evaluation of selected patients with Parkinson’s disease. J Am Geriatr Soc 4: 1219–1232PubMedGoogle Scholar
  11. 11.
    Evarts EV, Teravainen H, Calne DB (1981) Reaction time in Parkinson’s disease. Brain 106: 167–186CrossRefGoogle Scholar
  12. 12.
    Fahn S (in press) Methodology of drug trials in Parkinson’s disease. In: Capilideo R (ed) Methodology of drug trials in neurologic disordersGoogle Scholar
  13. 13.
    Fienbery SE (1983) The analysis of cross-classified categorial data, 2nd edn. MIT Press, Cambridge, MassGoogle Scholar
  14. 14.
    Folkerts JF, Njiokiktjien CJ (1971) The influence of L-dopa on the postural regulation of Parkinson patients. 1st Symposium international de posturographie, October 19–22, MadridGoogle Scholar
  15. 15.
    Hoaglin DC, Mosteller F, Tukey JW (eds) (1983) Understanding robust and exploratory data analysis. Wiley, New YorkGoogle Scholar
  16. 16.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  17. 17.
    Jansen EC, Larsen RE, Olesen MB (1982) Quantitative Romberg’s test. Acta Neurol Scand 66: 93–99PubMedCrossRefGoogle Scholar
  18. 18.
    Kartzinel R, Perlow MD, Carter AC, Chase TN, Calne DB, Shoulson I (1976) Metabolic studies with Bromocriptine in patients with idiopathic Parkinsonism and Huntington’s Chorea. Trans Am Neurol Assoc 101: 53–56PubMedGoogle Scholar
  19. 19.
    Knopp W (1968) Explorations in the assessment and meaning of the subclinical ex-trapyramidal effect of neuroleptic drugs. Pharmakopsychiatry 1: 54–62CrossRefGoogle Scholar
  20. 20.
    Knutsson E (1972) An analysis of Parkinsonian gait. Brain 95: 475–486PubMedCrossRefGoogle Scholar
  21. 21.
    Lakke JPWF, Van Praag HM et al. (1972) Predictive value of the probenecid test for the effect of L-dopa therapy in Parkinson’s disease. Nature 236: 208–209Google Scholar
  22. 22.
    Larsen TA, LeWitt PA, Calne DB (1983) Theoretical and practical issues in assessment of deficits and therapy in Parkinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 363–373Google Scholar
  23. 23.
    Larsen TA, Calne S, Calne DB (1984) Assessment of Parkinson’s disease. Clin Neuropharmacol 7 (2): 165–169PubMedCrossRefGoogle Scholar
  24. 24.
    Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Laihinen A, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB (1985) Positron emission tomography in Parkinson’s disease. Glucose and DOPA metabolism. Adv Neurol (in press)Google Scholar
  25. 25.
    Miller RG Jr (1981) Survival analysis. Wiley, New YorkGoogle Scholar
  26. 26.
    Potvin AR, Tourtellotte WW (1975) The neurological examination: advancements in its quantitation. Arch Phys Med 56: 425–437PubMedGoogle Scholar
  27. 27.
    Schoenberg BS, Anderson DW, Haerer AF (1985) Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845PubMedGoogle Scholar
  28. 28.
    Tatton WG, Eastman MJ, Bedingham W, Verrier MC, Bruce IC (1984) Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire on Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 136–143PubMedGoogle Scholar
  29. 29.
    Teravainen H, Calne DB (1980) Quantitative assessment of Parkinsonian deficits. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease: current progress, problems and management. Elsevier, North-Holland, pp 145–164Google Scholar
  30. 30.
    Teravainen H, Evarts EV, Calne DB (1980) Studies of Parkinsonian movement: 1. Programming and execution of eye movements. Acta Neurol Scand 62: 137–148PubMedCrossRefGoogle Scholar
  31. 31.
    Wagner HN, Burns HD, Dannais RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravart HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AY, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 1264–1266PubMedCrossRefGoogle Scholar
  32. 32.
    Ward CD, Sanes JN, Dambrosia JM, Calne DB (1983) Methods for evaluating treatment in Parkinson’s disease. Adv Neurol 37: 1–7PubMedGoogle Scholar
  33. 33.
    Webster DD (1968) Critical analysis of the disability in Parkinson’s disease. Mod Treat 5: 257–282PubMedGoogle Scholar
  34. 34.
    Webster DD, Mortimer JA (1977) Failure of L-dopa to relieve activated rigidity in Parkinson’s disease. In: Messiha et al. (eds) Parkinson’s disease. Neurophysiological, clinical and related aspects. Plenum, New York, pp 297–313Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • J. K. Tsui
  • M. Schulzer
  • D. B. Calne
    • 1
  1. 1.Division of Neurology, Department of MedicineUniversity of British Columbia, Health Sciences Centre HospitalVancouverCanada

Personalised recommendations